Open Outbreak

Malaria

Also known as: Plasmodium falciparum, Plasmodium vivax

Malaria is an infection caused by Plasmodium parasites. It usually spreads through bites from infected female Anopheles mosquitoes, not through ordinary contact with another person. Early symptoms include fever, headache and chills, usually starting 10–15 days after an infected bite. Malaria can be cured, but delayed treatment can be dangerous. Untreated Plasmodium falciparum infection can progress to severe illness and death within 24 hours. Young children, pregnant people, travellers and people with HIV or AIDS are particularly vulnerable. Malaria occurs mainly in tropical countries. WHO estimates that there were 282 million cases and 610,000 deaths worldwide in 2024, with about 95% of cases and deaths in its African Region. Prevention includes insecticide-treated bed nets, mosquito-bite protection and preventive medicines for eligible groups and travellers. Antimalarial medicines remain essential for treatment. The RTS,S/AS01 and R21/Matrix-M vaccines provide partial protection, so vaccination does not replace other precautions. Resistance to medicines and mosquito-control insecticides threatens progress.

Key facts

TransmissionMainly bites from infected female Anopheles mosquitoes. Also possible through infected blood, contaminated needles, organ transplantation and transmission from mother to baby before or during delivery; not through ordinary social contact.
IncubationSymptoms usually begin 10–15 days after an infected mosquito bite, according to WHO.
Case fatalityA general treated-versus-untreated case-fatality estimate is unknown from the retrieved sources. WHO reported a case-fatality ratio of 0.02% for Ethiopia's reported cases from 2024-01-01 through 2024-10-20; this is not a universal estimate or a treatment comparison.
Reproduction numberunknown
VaccineRTS,S/AS01 and R21/Matrix-M are approved malaria vaccines. Protection is partial; other prevention and treatment remain necessary.
TreatmentAntimalarial medicines; artemisinin-based combination therapies are established treatments for falciparum malaria. Vivax infection can relapse from persistent liver stages and needs treatment addressing those stages. Drug resistance can cause treatment failure.
ReservoirInfected humans contribute to the mosquito–human transmission cycle. The retrieved sources do not fully describe reservoirs for every malaria parasite species.
Endemic regionsMainly tropical countries. The greatest burden is in WHO's African Region. P. falciparum predominates in Africa; P. vivax predominates in most countries outside sub-Saharan Africa.

Transmission

Malaria usually spreads when an infected female Anopheles mosquito bites a person. Mosquitoes can acquire the parasite from infected people and carry it onward to others. This is different from direct spread through ordinary social contact: being near someone with malaria does not itself transmit the infection. Less common routes include blood transfusions, organ transplantation and sharing needles or syringes contaminated with infected blood. Infection can also pass from mother to baby before or during delivery. Prevention therefore centres on avoiding mosquito bites and reducing mosquito exposure. WHO recommends insecticide-treated bed nets, protective clothing, repellents and window screens, alongside locally appropriate mosquito-control measures.

Symptoms and severity

Fever, headache and chills are common early symptoms. WHO says these usually begin 10–15 days after an infected mosquito bite. They can resemble other illnesses, so testing early matters. Severe malaria can cause confusion, seizures, difficulty breathing, dark or bloody urine, jaundice and abnormal bleeding. These symptoms require emergency care. Untreated falciparum malaria can progress to severe illness and death within 24 hours. Infants, young children, pregnant people, travellers and people with HIV or AIDS face greater risk. Vivax malaria should not be dismissed as harmless; published evidence documents serious disease. The retrieved sources do not provide a universal fatality estimate comparing treated and untreated infections.

Treatment and vaccines

Malaria is curable, and early treatment can prevent mild illness from becoming severe. Antimalarial medicines remain central to care. Artemisinin-based combination therapies combine medicines and are established treatments for falciparum malaria, although resistance can reduce their effectiveness. Vivax malaria presents an additional problem: parasites can persist in the liver and cause later relapses. Treatment must address these persistent stages as well as the current illness. The RTS,S/AS01 and R21/Matrix-M vaccines provide partial protection, not complete protection. They do not replace mosquito-bite prevention or prompt treatment. Travellers should seek medical advice before departure about preventive medicines appropriate for their destination, rather than choosing medicines without guidance.

Where it occurs

Malaria is mostly found in tropical countries, but risk varies considerably within a country. WHO estimates that 80 countries had malaria cases in 2024. Its African Region accounted for about 95% of global cases and deaths that year. Falciparum malaria is the most prevalent form on the African continent and the deadliest malaria infection. Vivax malaria dominates in most countries outside sub-Saharan Africa; published literature describes its presence in Asia, Central and South America, and the Horn of Africa. Weather, mosquito habitats, population movements and access to prevention and treatment all influence local risk. Travellers need destination-specific advice rather than assuming an entire country has the same exposure.

Recent history

The site's archive contains seven malaria events, spanning notices from Tanzania in 1998 through the Democratic Republic of the Congo in 2024. This is a count of archived events, not all outbreaks worldwide. In Pakistan, WHO reported more than 3.4 million suspected cases during January–August 2022, with a surge after major floods. Ethiopia reported over 7.3 million cases and 1,157 deaths from 2024-01-01 through 2024-10-20; WHO assessed national risk as high. Its 2024-12-27 Congo notice described respiratory infections complicated by malaria, rather than an exclusively malaria outbreak. As of 2026-11-22, the site also lists an active Panama record, but the retrieved sources do not establish its current case totals or trajectory.

What to watch

Important warning signals include sustained increases in cases or deaths, transmission in new areas, and outbreaks continuing beyond the expected season. Expanding mosquito ranges also matter. WHO highlights Anopheles stephensi, an invasive mosquito that thrives in urban settings and has spread in Africa. Resistance to insecticides can weaken mosquito control, while resistance to antimalarial medicines can cause treatment failures. Flooding, conflict and disrupted health services can increase exposure or delay diagnosis and treatment. Access to bed nets, effective medicines and vaccines should therefore be monitored. Vaccine supply gaps would limit prevention, but the retrieved sources do not establish a current shortage. Ordinary person-to-person spread is not an established malaria transmission route.

Related outbreaks

Updated